Raltegravir: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Raltegravir''' (RAL, '''Isentress''', formerly MK-0518) is an [[antiretroviral drug]] produced by [[Merck & Co.]], used to treat [[HIV]] infection.<ref>{{cite journal |author=Savarino A |title=A historical sketch of the discovery and development of HIV-1 integrase inhibitors |journal=Expert Opin Investig Drugs |volume=15 |issue=12 |pages=1507–22 |year=2006 |month=December |pmid=17107277 |doi=10.1517/13543784.15.12.1507}}</ref> It received approval by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) on 12 October 2007, the first of a new class of HIV drugs, the [[Discovery and development of integrase inhibitors|integrase inhibitors]], to receive such approval.<ref name="fda_approval"> | |||
{{cite web | |||
| url = http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm124040.htm | |||
| title = FDA approval of Isentress (raltegravir) | |||
| date = June 25, 2009 | |||
| publisher = [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) | |||
| accessdate = 2009-11-15 | |||
}}</ref><ref name="fda_approval_package"> | |||
{{cite web | |||
| url = http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022145_Isentress.cfm | |||
| title =Isentress Drug Approval Package | |||
| date = February 22, 2008 | |||
| publisher = [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA) | |||
| accessdate = 2009-11-15 | |||
}}</ref> | |||
In December 2011, it received FDA approval for pediatric use in patients ages 2–18, taken in pill form orally twice a day by prescription with two other antiretroviral medications to form the cocktail (most [[Antiretroviral drug|anti-HIV drugs]] regimens for adults and children use these cocktails). Raltegravir is available in chewable form, but because the two tablet formulations are not interchangeable, the chewable pills are only approved for use in children two to 11. Older adolescents will use the adult formulation.<ref>http://www.everydayhealth.com/hiv-aids/1222/fda-okays-raltegravir-for-kids-teens-with-hiv.aspx?xid=aol_eh-hiv_6_20111219_&aolcat=HLT&icid=maing-grid7%7Cmain5%7Cdl10%7Csec3_lnk2%26pLid%3D122480</ref> | |||
==Category== | ==Category== | ||
Revision as of 00:04, 10 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Raltegravir (RAL, Isentress, formerly MK-0518) is an antiretroviral drug produced by Merck & Co., used to treat HIV infection.[1] It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.[2][3]
In December 2011, it received FDA approval for pediatric use in patients ages 2–18, taken in pill form orally twice a day by prescription with two other antiretroviral medications to form the cocktail (most anti-HIV drugs regimens for adults and children use these cocktails). Raltegravir is available in chewable form, but because the two tablet formulations are not interchangeable, the chewable pills are only approved for use in children two to 11. Older adolescents will use the adult formulation.[4]
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
References
- ↑ Savarino A (2006). "A historical sketch of the discovery and development of HIV-1 integrase inhibitors". Expert Opin Investig Drugs. 15 (12): 1507–22. doi:10.1517/13543784.15.12.1507. PMID 17107277. Unknown parameter
|month=ignored (help) - ↑ "FDA approval of Isentress (raltegravir)". U.S. Food and Drug Administration (FDA). June 25, 2009. Retrieved 2009-11-15.
- ↑ "Isentress Drug Approval Package". U.S. Food and Drug Administration (FDA). February 22, 2008. Retrieved 2009-11-15.
- ↑ http://www.everydayhealth.com/hiv-aids/1222/fda-okays-raltegravir-for-kids-teens-with-hiv.aspx?xid=aol_eh-hiv_6_20111219_&aolcat=HLT&icid=maing-grid7%7Cmain5%7Cdl10%7Csec3_lnk2%26pLid%3D122480